Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $103000.0.

  • Zentalis Pharmaceuticals' Gains from Investment Securities changed N/A to $103000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $634000.0, marking a year-over-year increase of 376.43%. This contributed to the annual value of $13000.0 for FY2024, which is 9784.05% down from last year.
  • Zentalis Pharmaceuticals' Gains from Investment Securities amounted to $103000.0 in Q3 2025.
  • Over the past 5 years, Zentalis Pharmaceuticals' Gains from Investment Securities peaked at $598000.0 during Q4 2023, and registered a low of -$124000.0 during Q4 2022.
  • Its 4-year average for Gains from Investment Securities is $132555.6, with a median of $66000.0 in 2024.
  • In the last 5 years, Zentalis Pharmaceuticals' Gains from Investment Securities tumbled by 142500.0% in 2024 and then surged by 110188.68% in 2025.
  • Zentalis Pharmaceuticals' Gains from Investment Securities (Quarter) stood at -$124000.0 in 2022, then soared by 582.26% to $598000.0 in 2023, then tumbled by 108.86% to -$53000.0 in 2024, then skyrocketed by 294.34% to $103000.0 in 2025.
  • Its Gains from Investment Securities was $103000.0 in Q3 2025, compared to $531000.0 in Q2 2025 and -$53000.0 in Q2 2024.